I believe OWCP is behaving like practically every

I believe OWCP is behaving like practically every biotech I've invested in that are on the Nasdaq or OTC, meaning they comply with SEC regulations and importantly, don't hype what they're doing. They do releases when they deem they're proper, and when they won't be considered as hype, they are either material events, which must be reported, or key events which they've indicated to shareholders that they would report, like the conclusion of safety trial.

Companies on the Pinks may comply with SEC guidance, but they get in no trouble if they don't, they likewise don't receive practically any review for hyping what they're doing. When OWCP is compared with RSII their are similarities in what they're saying they're doing, but RSII doesn't have the burden of proof that OWCP does. They can routinely issue PR's the SEC doesn't care, essentially they are self governing.

Anyone who's had Pinks hope that eventually they'll become fully compliant, move to the OTC, then on to the American or Nasdaq when they can qualify. It can happen, but if it fails to, the greatest value left in the company may be it's listing even though it's on the Pinks, and the company eventually gets bought out for it's shell, the original investors normally have their ownership dramatically reduced by a reverse split of perhaps 100 for 1, and then the company under new ownership issues a lot of new stock. For the old investor, the hope is that the new company will have tremendous success. I say this from personal experience, I don't sell companies that are still trading, but are practically worthless, and occasionally they do come back to life. In at least one case I did have a sub-penny Pink that made it onto the Nasdaq, it can happen.

I've seen some companies that make claims to the cure to practically every new medical problem, all with the same drug that has been through Phase 1 and 2 Trials. They announce that they're planning Phase 3 Trials with their drugs, and sound very confident that it will work. The stock moves up, they issue a lot more shares. The FDA won't deny them the right to spend their money in new trials, but so far it's failed in every applications. They've done numerous reverse splits to remain in the roughly $1 range. If next month we learn of a new threat to mankind, let's call it Lemon Flu, watch for the news releases.

Gary